Caspian Journal of Veterinary Sciences

Caspian Journal of Veterinary Sciences

Comparative evaluation of citral, silymarin, and thymoquinone in methotrexate-induced neurotoxicity: biochemical and histopathological evidence in rats

Document Type : Original Article

Authors
1 Department of Basic Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.
2 Department of Clinical Sciences, School of Veterinary Medicine, Shiraz University, Shiraz, Iran.
Abstract
Methotrexate (MTX) is an antineoplastic and immunosuppressive agent whose clinical use is limited by neurotoxicity, largely mediated through oxidative stress. Natural phytochemicals with antioxidant properties have emerged as promising candidates for preventing MTX-induced brain injury. Although the neuroprotective effects of silymarin, citral, and thymoquinone have been reported individually, their comparative efficacy against MTX-induced neurotoxicity has not been directly evaluated under identical experimental conditions. This study compared the neuroprotective effects of these phytochemicals in rats with MTX-induced neurotoxicity. Forty-two male Sprague-Dawley rats were randomly assigned to six groups (n = 7): healthy control, MTX, vehicle+MTX, MTX+silymarin, MTX+citral, and MTX+thymoquinone. MTX (20 mg/kg, intraperitoneally) was administered on day 3, while silymarin (50 mg/kg), citral (25 mg/kg), and thymoquinone (10 mg/kg) were injected intraperitoneally once daily for 10 days. Cerebral cortex total antioxidant capacity (TAC), malondialdehyde (MDA), and histopathological alterations were evaluated. MTX significantly reduced TAC and increased MDA levels compared to the healthy control group. Thymoquinone was the only treatment that significantly restored TAC compared to the MTX group (p < 0.01), whereas all three phytochemicals significantly reduced MDA levels (p < 0.05). Histopathological examination demonstrated marked neuronal degeneration, cytoplasmic microvacuolation, and darkly stained nuclei in MTX-treated rats, whereas all treatment groups exhibited improved neuronal morphology and reduced tissue injury. Overall, silymarin, citral, and thymoquinone attenuated MTX-induced neurotoxicity by reducing oxidative damage and improving histopathological alterations. Thymoquinone demonstrated the most favorable antioxidant profile by significantly restoring TAC, while all three compounds showed comparable efficacy in reducing lipid peroxidation and improving histopathological alterations.
Keywords
Subjects

Abbas, F; Eladl, MA; El-Sherbiny, M; Abozied, N; Nabil, A; Mahmoud, SM; Mokhtar, HI; Zaitone, SA and Ibrahim, D (2022). Celastrol and thymoquinone alleviate aluminum chloride-induced neurotoxicity: Behavioral psychomotor performance, neurotransmitter level, oxidative-inflammatory markers, and BDNF expression in rat brain. Biomed. Pharmacother., 151: 113072.
Abenavoli, L; Izzo, AA; Milić, N; Cicala, C; Santini, A and Capasso, R (2018). Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother. Res., 32: 2202-2213.
Ahmed, ZS O; Hussein, S; Ghandour, RA; Azouz, AA and El-Sakhawy, MA (2021). Evaluation of the effect of methotrexate on the hippocampus, cerebellum, liver, and kidneys of adult male albino rat: Histopathological, immunohistochemical and biochemical studies. Acta Histochem, 123: 151682.
Akhtar, MN; Saeed, R; Saeed, F; Asghar, A; Ghani, S; Ateeq, H; Ahmed, A; Rasheed, A; Afzaal, M and Waheed, M (2023). Silymarin: a review on paving the way towards promising pharmacological agent. Int. J. Food Prop., 26: 2256-2272.
Ashique, S; Mohanto, S; Kumar, N; Nag, S; Mishra, A; Biswas, A; Rihan, M; Srivastava, S; Bhowmick, M and Taghizadeh-Hesary, F (2024). Unlocking the possibilities of therapeutic potential of silymarin and silibinin against neurodegenerative Diseases-A mechanistic overview. Eur. J. Pharmacol., 981: 176906.
Aslani, MR; Saadat, S and Boskabady, MH (2024). Comprehensive and updated review on anti-oxidant effects of Nigella sativa and its constituent, thymoquinone, in various disorders. Iran. J. Basic Med. Sci., 27: 923-951.
Aslankoc, R; Savran, M; Doğuç, DK; Sevimli, M; Tekin, H and Kaynak, M (2022). Ameliorating effects of ramelteon on oxidative stress, inflammation, apoptosis, and autophagy markers in methotrexate-induced cerebral toxicity. Iran. J. Basic Med. Sci., 25: 1183.
Ayalon, I; Friedman, S; Binenbaum, Y; Oppenheimer, N; Shiran, S; Grisaru-Soen, G; Uliel-Sibony, S; Glatstein, M; Kaplan, JM and Sadot, E (2019). A case of methotrexate neurotoxicity presented as status epilepticus, encephalopathy, and high fever. J. Investig. Med. High Impact Case Rep., 7: 2324709619862311.
Bakhtiari, MK; Sharifiyazdi, H; Nazifi, S; Ghaemi, M and Zarandi, MH (2021). Effects of citral on serum antioxidant status and liver genes expressions of paraoxonase 1 and nitric oxide synthase in a rat model of streptozotocin-induced diabetes mellitus. Iran. J. Vet. Res., 22: 195.
Behairy, A; Elkomy, A; Elsayed, F; Gaballa, M M; Soliman, A and Aboubakr, M (2024). Antioxidant and anti-inflammatory potential of spirulina and thymoquinone mitigate the methotrexate-induced neurotoxicity. Naunyn Schmiedebergs Arch. Pharmacol., 397: 1875-1888.
Behdokht, B; Foad, NM; Saeed, N; Ahmadi, N and Sakineh, A (2024). Comparative study of the protective effects of citral, thymoquinone, and silymarin on methotrexate-induced cardiotoxicity in rats. J. Pharmacopuncture, 27: 245.
Cottin, V; Bendstrup, E; Bonniaud, P; Nasser, M; Spagnolo, P; Valenzuela, C and Kolb, M (2021). The case of methotrexate and the lung: Dr Jekyll and Mr Hyde.Eur. Respir. Soc. 57: 2100079.
Faraji, M; Noorbakhsh, MF; Kazemipour, N; Nazifi, S; Moradi, HR; Ahmadi, N and Azadmanesh, M (2025). Comparison of the effects of metformin, citral, Cymbopogon citratus extract and silver nanoparticles of Cymbopogon citratus extract on oxidative stress indices and Nrf2 levels in experimental type 2 diabetes in rats. Anim. Models Exp. Med. 8: 2128-2138.
Hamed, KM; Dighriri, IM; Baomar, AF; Alharthy, BT; Alenazi, FE; Alali, GH; Alenazy, RH; Alhumaidi, NT; Alhulayfi, DH and Alotaibi, YB (2022). Overview of methotrexate toxicity: a comprehensive literature review. Cureus, 14. e29518.
Idrees, M; Hakkim, FL; Naikoo, GA and Ul Hassan, I (2019). Recent advances in extraction, characterization, and potential use of citral.  Biotechnol. Bioeng. Mol. Approaches, 3: 225-236.
Jomova, K; Alomar, SY; Alwasel, SH; Nepovimova, E; Kuca, K and Valko, M (2024). Several lines of antioxidant defense against oxidative stress: antioxidant enzymes, nanomaterials with multiple enzyme-mimicking activities, and low-molecular-weight antioxidants. Arch. Toxicol., 98: 1323-1367.
Kandemir, FM; Kucukler, S; Caglayan, C; Gur, C; Batil, AA and Gülçin, İ (2017). Therapeutic effects of silymarin and naringin on methotrexate‐induced nephrotoxicity in rats: Biochemical evaluation of anti‐inflammatory, antiapoptotic, and antiautophagic properties. J. Food Biochem., 41: e12398.
Khatinasab, S; Kazemipour, N; Noorbakhsh, MF; Nazifi, S; Faraji, M and Ahmadi, N (2025). Evaluation of citral and green silver nanoparticles from Cymbopogon citratus extract on biochemical profile and nrf2 gene expression in liver tissue of type 2 diabetic rats. Biomed Res. Int., 2025: 9266092.
Kougkas, N; Dara, A; Pagkopoulou, E; Dimitriadou, A; Papadimitriou, E; Avdelidou, E; Garyfallos, A and Dimitroulas, T (2022). Methotrexate induced neurotoxicity in a patient with rheumatoid arthritis on rituximab therapy: a case-based review. Rheumatol. Int., 42: 1849-1854.
Li, CC; Yu, HF; Chang, CH; Liu, YT and Yao, HT (2018). Effects of lemongrass oil and citral on hepatic drug-metabolizing enzymes, oxidative stress, and acetaminophen toxicity in rats. J. Food Drug Anal., 26: 432-438.
Mohamed, AE; El-Magd, MA; El-Said, KS; El-Sharnouby, M; Tousson, EM and Salama, AF (2021). Potential therapeutic effect of thymoquinone and/or bee pollen on fluvastatin-induced hepatitis in rats. Sci. Rep., 11: 15688.
Nakamura, Y; Miyamoto, M; Murakami, A; Ohigashi, H; Osawa, T and Uchida, K (2003). A phase II detoxification enzyme inducer from lemongrass: identification of citral and involvement of electrophilic reaction in the enzyme induction. Biochem. Biophys. Res. Commun., 302: 593-600.
Perez, JL; Jayaprakasha, GK; Cadena, A; Martinez, E; Ahmad, H and Patil, BS (2010). In vivo induction of phase II detoxifying enzymes, glutathione transferase and quinone reductase by citrus triterpenoids. BMC Complement. Altern. Med., 10: 1-8.
Sakineh, A; Noorbakhsh, MF; Ahmadi, N; Saeed, N and Behdokht, B (2023). Evaluation of the protective effect of citral, silymarin, and thymoquinone on methotrexate-induced lung injury in rats. J. Pharmacopuncture, 26: 184.
Sayyad, M; Sutar, AD; Shivhare, K; Shukla, R and Flora, SJS (2025). Silymarin as a phytopharmaceutical agent: advances in mechanistic insights, formulation strategies, and pre-clinical applications. Eur. Respir. Soc., 16: 1711653.
Su, YW; Chen, KM; Hassanshahi, M; Tang, Q; Howe, PR and Xian, CJ (2017). Childhood cancer chemotherapy–induced bone damage: pathobiology and protective effects of resveratrol and other nutraceuticals. Ann. N. Y. Acad. Sci., 1403: 109-117.
Vezmar, S; Becker, A; Bode, U and Jaehde, U (2003). Biochemical and clinical aspects of methotrexate neurotoxicity. Chemother., 49: 92-104.
Watanabe, K; Arakawa, Y; Oguma, E; Uehara, T; Yanagi, M; Oyama, C; Ikeda, Y; Sasaki, K;Isobe, K and Mori, M (2018). Characteristics of methotrexate-induced stroke-like neurotoxicity. Int. J. Hematol., 108: 630-636.
Xu, M; Wu, S; Wang, Y; Zhao, Y; Wang, X; Wei, C; Liu, X; Hao, F and Hu, C (2022). Association between high-dose methotrexate-induced toxicity and polymorphisms within methotrexate pathway genes in acute lymphoblastic leukemia. Eur. Respir. Soc., 13: 1003812.
Yardım, A; Kucukler, S; Özdemir, S; Çomaklı, S; Caglayan, C; Kandemir, FM and Çelik, H (2021). Silymarin alleviates docetaxel-induced central and peripheral neurotoxicity by reducing oxidative stress, inflammation and apoptosis in rats. Gene, 769: 145239.

Articles in Press, Accepted Manuscript
Available Online from 16 November 2026

  • Receive Date 09 July 2026
  • Revise Date 27 July 2026
  • Accept Date 27 July 2026